Q2 sales rose 5% year-over-year to $10.9B, with record $105B backlog and strong growth across all segments. Guidance for 2026 was raised for sales, EPS, and book-to-bill, reflecting robust demand and operational execution. Margins were impacted by specific program EACs, but corrective actions are underway.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.